EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

Kai Zhao iD, Madita Braun, Leonie Meyer, Katharina Otte, Hartmann Raifer, Frederik Helmprobst, Vincent Möschl, Axel Pagenstecher iD, Hans Urban, Michael W Ronellenfitsch iD, Joachim P Steinbach, Jelena Pesek und 7 weitere

Cells · 2024

DOI: 10.3390/cells13070632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Kai Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Philipps University Marburg, Baldingerstraße 1, 35043 Marburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Amides, Pyrimidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Gießen und Marburg, University Hospital UKGM, “Deutsche Krebshilfe” (German Cancer Aid).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2-family proteins. We assessed TMZ, Methotrexate (MTX), and Cytarabine (Ara-C) (apoptosis inducers) combined with XPO1/Bcl-2/Mcl-1-inhibitors (apoptosis rescue) in GB cell lines and primary GB stem-like cells (GSCs). Using CellTiter-Glo® and Caspase-3 activity assays, we generated dose–response curves and analyzed the gene and protein regulation of anti-apoptotic proteins via PCR and Western blots. Optimal drug combinations were examined for their impact on the cell cycle and apoptosis induction via FACS analysis, paralleled by the assessment of potential toxicity in healthy mouse brain slices. Ara-C and MTX proved to be 150- to 10,000-fold more potent in inducing apoptosis than TMZ. In response to inhibitors Eltanexor (XPO1; E), Venetoclax (Bcl-2; V), and A1210477 (Mcl-1; A), genes encoding for the corresponding proteins were upregulated in a compensatory manner. TMZ, MTX, and Ara-C combined with E, V, and A evidenced highly lethal effects when combined. As no significant cell death induction in mouse brain slices was observed, we conclude that this drug combination is effective in vitro and expected to have low side effects in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAntineoplastic AgentsAmidesPyrimidinesSulfonamidesBridged Bicyclo Compounds, HeterocyclicAnimalsMiceTemozolomideMethotrexateCytarabineAntineoplastic Agents, AlkylatingCell Line, TumorApoptosis

Stichwörter der Autor:innen

Ara-CBcl-2MTXMcl-1SINETMZXPO1cytarabineeltanexorglioblastomamethotrexatetemozolomidevenetoclax

Substanzen

TemozolomideMethotrexatevenetoclaxCytarabineEltanexorAntineoplastic Agents, AlkylatingAntineoplastic AgentsAmidesPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Neurosurgery, Philipps University Marburg, Baldingerstraße 1, 35043 Marburg, Germany.
  • Department of Hematology, Oncology & Immunology, Philipps University Marburg, Baldingerstraße 1, 35043 Marburg, Germany.
  • FACS Core Facility, Philipps University Marburg, Hans-Meerwein-Straße 3, 35043 Marburg, Germany.
  • Department of Neuropathology, Philipps University Marburg, Baldingerstraße 1, 35043 Marburg, Germany.
  • University Cancer Center (UCT) Frankfurt-Marburg, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
  • Dr. Senckenberg Institute of Neurooncology, Goethe-University of Frankfurt, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany.

ORCID-Profile: Kai Zhao, Axel Pagenstecher, Michael W Ronellenfitsch, R Verena Taudte, Andreas Neubauer, Christopher Nimsky, Jörg W Bartsch, Tillmann Rusch

Förderung

  • Universitätsklinikum Gießen und Marburg
  • University Hospital UKGM
  • “Deutsche Krebshilfe” (German Cancer Aid)
  • German José Carreras Leukemia foundation

Zitieren

APA

Zhao, K., Braun, M., Meyer, L., Otte, K., Raifer, H., Helmprobst, F., Möschl, V., Pagenstecher, A., Urban, H., Ronellenfitsch, M. W., Steinbach, J. P., Pesek, J., Watzer, B., Nockher, W. A., Taudte, R. V., Neubauer, A., Nimsky, C., Bartsch, J. W., & Rusch, T. (2024). A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. Cells. https://doi.org/10.3390/cells13070632

Vancouver

Zhao K, Braun M, Meyer L, Otte K, Raifer H, Helmprobst F, et al. A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. Cells. 2024. doi:10.3390/cells13070632

BibTeX
@article{Zhao2024,
  author = {Zhao, Kai and Braun, Madita and Meyer, Leonie and Otte, Katharina and Raifer, Hartmann and Helmprobst, Frederik and Möschl, Vincent and Pagenstecher, Axel and Urban, Hans and Ronellenfitsch, Michael W and Steinbach, Joachim P and Pesek, Jelena and Watzer, Bernhard and Nockher, Wolfgang A and Taudte, R Verena and Neubauer, Andreas and Nimsky, Christopher and Bartsch, Jörg W and Rusch, Tillmann},
  title = {A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13070632}
}
Kostenlos starten →